| Unique pattern of ET‐743 activity in different cellular systems with defined deficiencies in DNA‐repair pathways G Damia, S Silvestri, L Carrassa, L Filiberti, GT Faircloth, G Liberi, ... International journal of cancer 92 (4), 583-588, 2001 | 206 | 2001 |
| DNA damage response inhibitors: Mechanisms and potential applications in cancer therapy L Carrassa, G Damia Cancer treatment reviews 60, 139-151, 2017 | 174 | 2017 |
| Cisplatinum and taxol induce different patterns of p53 phosphorylation G Damia, L Filiberti, F Vikhanskaya, L Carrassa, Y Taya, M Dincalci, ... Neoplasia 3 (1), 10-16, 2001 | 138 | 2001 |
| Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo L Carrassa, R Chilà, M Lupi, F Ricci, C Celenza, M Mazzoletti, M Broggini, ... Cell Cycle 11 (13), 2507-2517, 2012 | 135 | 2012 |
| PQR309 is a novel dual PI3K/mTOR inhibitor with preclinical antitumor activity in lymphomas as a single agent and in combination therapy C Tarantelli, E Gaudio, AJ Arribas, I Kwee, P Hillmann, A Rinaldi, ... Clinical Cancer Research 24 (1), 120-129, 2018 | 118 | 2018 |
| Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing, or not, p53 L Carrassa, M Broggini, E Erba, G Damia Cell Cycle 3 (9), 1175-1179, 2004 | 111 | 2004 |
| Unleashing Chk1 in cancer therapy L Carrassa, G Damia Cell cycle 10 (13), 2121-2128, 2011 | 97 | 2011 |
| Recent insights into mucinous ovarian carcinoma F Ricci, R Affatato, L Carrassa, G Damia International journal of molecular sciences 19 (6), 1569, 2018 | 88 | 2018 |
| Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma R Chilà, A Basana, M Lupi, F Guffanti, E Gaudio, A Rinaldi, L Cascione, ... Oncotarget 6 (5), 3394, 2014 | 73 | 2014 |
| Unique features of the mode of action of ET-743 M D'Incalci, E Erba, G Damia, E Galliera, L Carrassa, S Marchini, ... The Oncologist 7 (3), 210-216, 2002 | 67 | 2002 |
| U2OS cells lacking Chk1 undergo aberrant mitosis and fail to activate the spindle checkpoint L Carrassa, Y Sanchez, E Erba, G Damia Journal of cellular and molecular medicine 13 (8a), 1565-1576, 2009 | 60 | 2009 |
| Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2 G Rastelli, A Anighoro, M Chripkova, L Carrassa, M Broggini Cell Cycle 13 (14), 2296-2305, 2014 | 54 | 2014 |
| The ETS inhibitors YK-4-279 and TK-216 are novel antilymphoma agents F Spriano, EYL Chung, E Gaudio, C Tarantelli, L Cascione, S Napoli, ... Clinical Cancer Research 25 (16), 5167-5176, 2019 | 53 | 2019 |
| Checkpoint kinase 1 down-regulation by an inducible small interfering RNA expression system sensitized in vivo tumors to treatment with 5-fluorouracil M Ganzinelli, L Carrassa, F Crippa, M Tavecchio, M Broggini, G Damia Clinical Cancer Research 14 (16), 5131-5141, 2008 | 50 | 2008 |
| Characterization of the 5’flanking region of the human Chk1 gene: identification of E2F1 functional sites L Carrassa, M Broggini, F Vikhanskaya, G Damia Cell Cycle 2 (6), 603-608, 2003 | 47 | 2003 |
| DNA damage response inhibitor combinations exert synergistic antitumor activity in aggressive B-cell lymphomas V Restelli, M Lupi, R Chilà, M Vagni, C Tarantelli, F Spriano, E Gaudio, ... Molecular cancer therapeutics 18 (7), 1255-1264, 2019 | 44 | 2019 |
| The cytotoxic effect of unconjugated bilirubin in human neuroblastoma SH-SY5Y cells is modulated by the expression level of MRP1 but not MDR1 L Corich, A Aranda, L Carrassa, C Bellarosa, JD Ostrow, C Tiribelli Biochemical Journal 417 (1), 305-312, 2009 | 37 | 2009 |
| Targeting non-canonical activation of GLI1 by the SOX2-BRD4 transcriptional complex improves the efficacy of HEDGEHOG pathway inhibition in melanoma S Pietrobono, E Gaudio, S Gagliardi, M Zitani, L Carrassa, F Migliorini, ... Oncogene 40 (22), 3799-3814, 2021 | 35 | 2021 |
| Identification of PLK1 as a new therapeutic target in mucinous ovarian carcinoma R Affatato, L Carrassa, R Chilà, M Lupi, V Restelli, G Damia Cancers 12 (3), 672, 2020 | 34 | 2020 |
| BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance C Tarantelli, E Bernasconi, E Gaudio, L Cascione, V Restelli, AJ Arribas, ... ESMO open 3 (6), e000387, 2018 | 29 | 2018 |
